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Abstract
Nuclear receptors (NRs) form a large family of transcription factors (48 human
members) and have critical roles in nearly all aspects of vertebrate development and
adult physiology by transducing the effects of small, lipophilic compounds into
transcriptional response. The ligand-binding domains (LBDs) of most NRs consist of
11 to 13 -helices that form a characteristic, 3-layer anti-parallel -helical sandwich.
Adopted orphan NRs such as constitutive androstane receptor (CAR), peroxisome
proliferator-activated receptors (PPARs) and the classical endocrine receptor for
vitamin D (VDR) show distinct functional, biochemical and physiological properties
originating from their protein structures.
The main objective of the present study was to gain more insight into the
structure-function relationship of PPARs, CAR and VDR using molecular dynamics
simulations and structural analysis as tools. The results confirmed that although
these receptors show high amino acid and spatial conservation in their LBDs they
display major differences in the ligand recognition, in the affinity for coactivators
and corepressor and in the LBD dynamics, which lead to conformational changes
resulting in activation or inactivation of the receptor. All of the above mentioned
processes are tightly connected with the dynamics of the most C-terminal helix of the
LBD, called helix 12.
CAR and PPARs are of additional interest since they display exceptionally high
constitutive activity, which originates in the ligand-independent CoA interaction.
The data of the presented studies show that the molecular mechanism of this
function is an intra- and extramolecular stabilization of the helix 12 via residues in
helices 3, 4-5 and 11. In the case of PPARs there are at least four groups of amino
acids to stabilize the helix 12. Some of the interactions are evolutionary conserved
between both receptors. These findings suggest that the modulation of activity of
these receptors is possible not only by increasing their activity using receptor specific
agonists but also by lowering it via inverse agonists.
In conclusion, the studies presented in this doctoral thesis increased our
knowledge on the structure-function relationship of NRs and provided detailed
perception for understanding the molecular basis of ligand-recognition, cofactor
interaction of the NRs and dynamic properties of activation and inactivation of these
receptors.
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Chapter 1
1 Introduction
During evolution most biological systems have had a tendency to increase their
complexity. This trend also applies for the molecular processes occurring in cells
such as replication, transcription and translation. They demand a strict level of
organization and regulation since they involve multifunctional complexes and huge
protein machineries.
One of the mentioned processes, transcription, requires such multitasking
regulatory complexes containing rather diverse selection of nucleic acids and
proteins with highly specific but distinguished functions. These complexes contain,
amongst others, transcription factors, coregulators, and proteins with specific
enzymatic activities, which makes their exploration and investigation challenging.
Luckily, modern study approaches gave rise to the research fields that try to
answer the questions concerning the detailed molecular understanding of these
processes by looking at a limited number of components at one time. One of the
fields, structural biology, includes tools such as structural analyses that are useful in
answering these questions.
Structural analysis is an approach trying to connect three dimensional protein
structures with the function of the proteins. Usually certain amino acids are
responsible for distinct functions in a protein such as catalytic activity, ligand
binding, DNA binding and dimerization. Looking on the one or the other function
separately can create very simple model with biased views. For example, certain
amino acids are directly involved in the catalytic activity of the protein and they are
essential for it. However, if we try to look at these processes in parallel the picture
gains in its complexity and the dynamic sequence of actions can be recognized. As a
direct example of this kind of continuity of causes is the binding of the ligand in the
ligand-binding pocket of a receptor that induces conformational changes altering
protein interactions on the surface of the protein. Exploration of these continual
dynamic changes is a very difficult task since there is limited number of methods,
"It is those who get lost, who find the new ways."
Nils Kjaer (1870-1924)
Norwegian writer
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which can be used to observe proteins in their native environment and consequently
measure the dynamic changes of their functional properties.
Most of the available techniques allow the measurement of functionality of a
protein at a certain time point, which makes the obtained data more characteristic for
the static state of the molecule at the beginning of the experiment. At the intersection
of these two technical approaches are the in silico methods where molecular
dynamics (MD) simulations play a very important role. These allow for a more
dynamic view of processes and are very important tools in the investigation of the
series of actions such as the impact of conformational changes on protein-protein
interactions.
This thesis extends the research on the molecular mechanism of the transcription
regulation via nuclear receptors (NRs) using structural analysis and MD simulations.
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Chapter 2
2 Review of Literature
The NR family has the largest number of members of any class of transcription
factors. The completion of the Human Genome Project allowed the definition of the
complete functional set of 48 NR genes [Robinson-Rechavi et al., 2001]. In contrast, in
the genome of D. melanogaster there have been identified 21 NRs [Adams et al., 2000],
whereas in the nematode C. elegans their number is more than 270 [Sluder et al.,
2001]. Below will be discussed the present knowledge of the molecular biology of
this class of proteins as well as cofactors, which have been found to interact with
them.
2.1 The NR superfamily
NRs are characteristic of multi-cellular organisms and in many cases their
activity can be modulated via small lipophilic compounds (ligands). For example,
non-polar compounds, such as steroid hormones, fatty acids, cholesterol derivates or
xenobiotics, can act as ligands for NRs. In this respect they behave as ligand-gated
transcriptional switches. In response to the presence of these ligands, NRs regulate
the expression of target genes to affect processes such as mineral homeostasis,
reproduction, development and metabolism [Chawla et al., 2001]. Since many of the
ligands for NRs are products or potential metabolites of NRs’ target gene action they
provide a direct link between signaling molecules controlling the processes and
molecular responses. Like other transcription factors, NRs work in concert with other
proteins to achieve their effect. These proteins fall into two broad classes, namely
coactivators (CoA) and corepressors (CoR), which are defined by the way they
activate or repress NR action. These proteins in conjunction regulate NRs to achieve
primarily chromatin remodeling events which lead to activation or suppression of
target gene expression [Glass et al., 2000] (Fig. 2.1). As mentioned already above the
fact that NRs can bind small molecules makes them suitable for “smart” drug design
because their size makes them readily synthesizable. In addition, NRs regulate many
Review of Literature
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our genes, which are often clustered into functional groups related to a pathological
processes and thereby targeting of NRs may change the course of a disease in many
cases. These interventions may be beneficial for controlling physiological cascades
associated with major diseases (e.g. cancer, osteoporosis and type 2 diabetes).
Fig. 2.1 The activation of NRs by ligands and the regulation of target genes. Small
lipophilic compounds (Ligand, red) binds to the NR in the cytoplasm or the nucleus. The
NR binds to the specific DNA sequence in the regulatory region of the target gene.
Depending on the property of the ligand, NR interacts with CoA or CoR. In the case of
activation, the basal transcription machinery is recruited and the target gene is up-
regulated.
2.1.1 Classification of the NRs
NRs have been classified using evolutionary criteria, based on primary
sequences of their genes and proteins or similarities in their functional profiles such
as ligand affinity, ligand binding, or dimerization. Taking evolution into account,
NRs can be divided into six related subfamilies, NR0-NR5 and 28 groups of receptors
according to DNA sequence homology of DNA-binding domains (DBDs) and ligand-
binding domains (LBDs) [The NR nomenclature committee, 1999].
The functional division of the superfamily based on affinities and properties of
the ligands includes three subfamilies (Table 2.1). In the first group there are classical
endocrine NRs, “receptors” that can bind high-affinity hormonal lipids in a
concentration 1 nM or lower [Chawla et al., 2001]. In this group, receptors for the
hormones 3,5,3’-triiodothyroine (TRs, [Sap et al., 1986; Weinberger et al., 1986]), all-
trans retinoic acid (RARs, [Petkovich et al., 1987]), 1,25(OH)2D3 (VDR, [Baker et al.,
Review of Literature
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1988]), 17-estradiol (ER, ), cortisol (GR), aldosterone (MR), progesterone (PR) and
dihydrotestosterone (AR) are to be found.
Table 2.1 The human NR superfamily.
Subfamily Name Nomenclature Ligand*
AR NR3C4 dihydrotestosterone
ER, NR3A1, NR3A2 17-estradiol
GR NR3C1 cortisol
MR NR3C2 aldosterol
PR NR3C3 progesterone
RAR, ,  NR1B1, NR1B2, NR1B3 all-trans retinoic acid
TR,  NR1A1, NR1A2 3,5,3’-triiodothyronine
Receptors
VDR NR1I1 1,25(OH)2D3
CAR NR1I3 androstanol, xenobiotics
ERR, ,  NR3B1, NR3B2, NR3B3 anti-estrogens
FXR NR1H4 bile acids
HNF-4,  NR2A1, NR2A2 fatty acids
LRH-1 NR5A2 phospholipids
LXR,  NR1H2, NR1H3 oxysterols
PPAR, ,  NR1C1, NR1C2, NR1C3 fatty acids and itsderivatives
PXR NR1I2 pregnanedione,
xenobiotics
ROR, ,  NR1F1, NR1F2, NR1F3 fatty acids, cholesterol,
retinoids
RXR, ,  NR2B1, NR2B2, NR2B3 retinoids, fatty acids
Sensors
SF-1 NR5A1 phospholipids
COUP, ,  NR2F1, NR2F2, NR2F3
DAX NR0B1
GCNF NR6A1
NGFI-B, ,  NR4A1, NR4A2, NR4a3
PNR NR2E3
RevErbA,  NR1D1, NR1D2
SHP NR0B2
TLX NR2E1
Orphans
TR2,  NR2C1, NR2C2
unknown
* synthetic or natural compounds co-crystallized with NRs, which have or may have
physiological effects.
The second group covers “sensors” for xenobiotics and nutritional components
such as fatty acids, lipids and cholesterol. These sensors are recognizing their ligand
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mostly in micromolar range. In this group, we can find sensors for fatty acids (PPAR,
[Desvergne et al., 1999]), oxysterols (LXRs, [Repa et al., 2000]), bile acids (FXR, [Mi et
al., 2003]) and xenobiotics (PXR and CAR, [Honkakoski et al., 2003]). In addition, to
this group belong the RXR isotypes, receptors for the natural ligand 9-cis retinoic
acid, which are probably the most prominent adopted orphan NRs since many other
NRs make heterodimers with them [Mangelsdorf et al., 1990]. The heterodimerization
is inevitable for the biological function of many of these receptors.
The third group of NRs is called “real orphans” because to date no high affinity
ligand has been identified for them. It should be noted that many of the sensors
when first cloned were described as orphans and when ligands were found for them,
they became adopted orphans. This term is still widely used in the literature.
2.1.2 Three-dimensional and functional organization of the NRs
The functional and structural organization of NRs is highly conserved with most
of them containing specific domains such as activation function–1 (AF-1), DBD,
hinge region, LBD and activation function–2 (AF-2). However, it should be noted
that the conservation of these domains varies throughout the NR family (Fig. 2.2).
Specific NRs lack some of these domains, VDR lacks an AF-1, the orphan NRs SHP
and DAX lack DBD and RevErb lacks an AF-2 domain.
Fig. 2.2 Schematic overview of the functional domains of NRs. NRs consist of different
domains that are connected with a distinct function of the protein. The least conserved
region is the C-terminal region (E-F), which may vary in length and the AF-1 domain that
can contains sites for CoA binding. Some receptors contain an additional F domain. The
DNA-binding domain (DBD), which contains two zinc fingers, is the most conserved
region and contains several functional domains (P-, D-, T- and A-box). The hinge region
serves as a connector between DBD and the ligand-binding domain (LBD). It has very
critical parts that serve for ligand recognition, heterodimerization and cofactor
interaction. In addition, at the very end of the LBD the AF-2 (helix 12) is localized, which
is crucial for ligand dependent conformational changes of the receptor
Review of Literature
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2.1.2.1 Activation function-1 domain
This domain is the part of the A/B region (Fig. 2.2), which is a modulatory region
of variable size and sequence. The A/B domain is one of the most diverse parts of
NRs, i.e. its sequence is not well conserved among the NRs. In many cases the
function of this region is dependent on covalent modifications of its respective amino
acid residues. There are several studies, which indicate that this domain in NRs can
be phosphorylated by cyclin-dependent kinases and/or mitogen-activated protein
kinases (MAPK) and this modification influences ligand-dependent and
-independent transactivation function of the receptor [Kato et al., 1995; Patrone et al.,
1996; Rochette-Egly et al., 1997; Rochette-Egly et al., 1992; Taneja et al., 1997]. In
PPAR the AF-1 domain is also modulated via MAPK phosphorylation, which
results in enhancement of the transcriptional activity of the receptor [Juge-Aubry et
al., 1999]. In contrast to this, the phosphorylation by the same kinase on the PPAR
AF-1 results in the negative regulation of the receptor. Surprisingly, this
posttranslational modification has a negative impact on the ligand-binding to the
receptor, suggesting that the regulation of the transcriptional activity involves an
intramolecular communication between the modulatory domains AF-1 and AF-2
(helix 12), which is located at the opposite end of the molecule [Shao et al., 1998].
Furthermore, AF-1 can have a direct interaction with CoAs as it is the case for PGC-2
that interacts with the AF-1 of the PPAR2 NR [Castillo et al., 1999].
2.1.2.2 DNA-binding domain
The DBD is the most conserved region in NRs, which confers their specific
mechanism of action concerning the recognition of specific target sequence and the
activation of nearby target gene. This domain contains amino acid residues, which
are highly conserved among the members of the NR superfamily and are required
for efficient DNA binding of the receptor. The DBD includes two “zinc-finger” motifs
that consist of four conserved cysteine residues each, which bind and hold in place
one zinc atom (Fig. 2.3) [Luisi et al., 1991; Schwabe et al., 1993; Shaffer et al., 2002].
Besides the zinc-finger binding motifs that span usually 60-70 amino acids, there is a
carboxy-terminal extension, which contains the so-called T- and A-boxes. Amino
acids essential for the specific DNA recognition are located in the first zinc-finger in
the region called P-box. NRs typically bind to the DNA sequences with the
conserved hexanucleotide motif. In addition, the DBD is involved in the dimerization
of NRs through the specific amino acids located in the region called D-box, which is
in the second zinc-finger. The core of the DBD contains two
-helices, the first helix starting from the third cysteine residue of the first zinc-finger
and the second one spans the carboxy terminus of the second zinc-finger (Fig. 2.3).
2.1.2.3 Hinge region
The hinge region, which is sometimes also called domain D (Fig. 2.2) with
respect bridges the DBD and the LBD and allows the rotation of these two domains
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selective to each other. In many cases it also contains a nuclear localization signal and
also some residues that have been shown to be important for CoR interaction [Chen
et al., 1995; Hörlein et al., 1995].
Fig. 2.3 Crystal structure of the human VDR DBD. The DBD consist of a highly
conserved 66 amino acid stretch whose core is made up from two zinc fingers (red
spheres) each contacted by four cysteine residues. The polypeptide chain around the zinc
nuclei modules is folded into unified globular domains containing two -helices (blue)
and -strands (red). The last adjacent helix is the C-terminal extension that may contain
motifs for dimerization.
2.1.2.4 Ligand-binding domain
The LBD is a multifunctional domain involved primarily in the ligand
recognition. It has also been shown to be responsible for dimerization with LBDs of
other NRs and interactions with heat shock proteins as well as CoAs and other
components of the basal transcriptional machinery. To date many crystal structures
containing the LBDs of NRs have been solved that show rather similar canonical
structures for different members of the NR superfamily. From the structural point of
view (Fig. 2.4) the LBDs of most NRs are a characteristic 3-layer anti-parallel -helical
sandwich formed by 11 - 13 individual -helices. The part of the LBD formed by
helices 1, 8, 9, 10 and the upper part of helix 3 (Fig. 2.4) is structurally highly
conserved among the members of the NR superfamily and shows less dynamic
movements. Helices 4, 5, 6, 7, 11, 12 and the lower part of the helix 3 (Fig. 2.4) form a
cavity of the ligand-binding pocket, which has the ability to adopt its volume
according to the bound ligand. This part of the LBD displays the highest flexibility
and dynamics [Molnár et al., 2005; Nagy et al., 2004; Nolte et al., 1998]. For detailed
description of the LBDs see Chapters 2.2.1, 2.3.1 and 2.4.1.
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Fig. 2.4 3D-view of the structurally conserved NR LBD. The two views represent the
same molecule turned 270°.The LBD of most NRs is a characteristic 3-layer anti-parallel
-helical sandwich formed by 11-13 -helices. The three layers are depicted in color (red,
blue and green). Helices h6 and h12 (light brown) make the lid of the LBD. The -sheets
are highlighted in light blue.
2.1.2.5 Helix 12 (AF-2 domain)
The helix 12 (Fig. 2.2 and 2.4) is considered to be the very last helix of the LBD,
and its main function is to respond to ligand-triggered conformation change of the
receptor allowing the docking of the CoA to LBD. In the whole receptor this part
undergoes the biggest conformational changes and the direct effect of the ligand is
also mediated through this domain [Li et al., 2003].
2.1.2.6 Ligand-binding pocket
The ligand-binding pocket is the cavity inside the LBD of the NR, which contains
amino acids essential for the recognition of the ligand. This pocket is mainly
hydrophobic and is buried in the lower, more flexible, part of the LBD allowing the
accommodation of its shape for the different non-polar ligands bound into the cavity
of the ligand-binding pocket. Its lining is constructed from residues derived from the
helices 3, 4, 6, 7, 11 and 12. Ligand-binding pockets vary in size among the receptors
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from  0 Å3 in the Nurr-1, which does not have a functional ligand-binding pocket, to
 1400 Å3 in the mammalian PPAR subtypes. However, it is very difficult to calculate
the exact volume of the apo-receptor ligand-binding pocket, because the space of the
pocket may considerably change within the same receptor depending on the volume
of the ligand [Li et al., 2003].
2.2 CAR
The human NR CAR (initially called MB67) was cloned in 1994 by using
degenerated oligonucleotide probes against the conserved NR sequence motif in the
DBD. Three years later the mouse orthologue was isolated [Baes et al., 1994; Choi et
al., 1997]. An amino acid comparison of human CAR relative to human PXR, another
orphan NR, results in an amino acid residue identity of 66 % and 45 % for the DBD
and the LBD, respectively. In addition, like plenty of other NRs, CAR dimerizes with
RXR. CAR is most abundantly expressed in the liver and intestine.
2.2.1 3D-protein structure of the human and mouse CAR LBDs
CAR was one of the most recent NRs to be crystallized and to date there are four
different LBD crystal structures available (Table 2.1). Three of them represent either
human or mouse CAR in an active conformation whilst the other one is mouse CAR
in an inactive conformation. All crystal structures share the canonical 3-layer -
helical sandwich architecture typical for other NR LBDs. However, some of the
helices that contribute to the LBD structure differ slightly in their composition. Both
human and mouse CAR contain in their respective active conformation, 11 -helices,
two 310 helices (helix 2 and helix 2’) and three short -strands [Suino et al., 2004; Xu et
al., 2004].
Table 2.1 The human and mouse CAR crystal structures.
PDB
ID Molecules Ligand
Resolution
from PDB
header
Resolution
from map
calculation
Complete
-ness of
data
R value
(free R)
from PDB
header
R
value
for
map
Reference
1XVP hCAR-RXR
CITCO
Penta-decanoic
acid
2.60 Å -* 86.3 % 0.180(0.234) -*
[Xu et al.,
2004]
1XV9 hCAR-RXR
5-pregnanedione
C16-C18 FA 2.70 Å -* 86.4 %
0.181
(0.239) -*
[Xu et al.,
2004]
1XLS mCAR-RXR
TCPOBOP
9cRA 2.96 Å
19.99 –
1.97 Å 92.9 %
0.255
(0.303) 0.276
[Suino et
al., 2004]
1XNX mCAR Androstanol 2.90 Å 29.54 –2.90 Å 100.0 %
0.229
(0.288) 0.241
[Shan et
al., 2004]
* the electron density map is not available
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Interestingly, mouse CAR in the inactive conformation contains 12 -helices with
helix 2 being absent. Despite this, the rest of the molecule has an identical structural
fingerprint when compared to the active CAR LBD. The inactive mouse CAR LBD
shares the highest structural similarity with human PXR with root-mean-square
deviation (rmsd) = 0.76 for 155 C atoms, sequence identity of 35.1 %, and VDR with
rmsd = 0.97 for 155 C atoms, sequence identity of 30.8 % [Shan et al., 2004]. Some
additional interesting features occur in the CAR LBD, including the occurrence of the
shortest known helix 12 for a NRs and the appearance of an additional helix called
“X” that is located between helices 11 and 12 (Fig. 2.5). This latter structural feature is
also present in other NRs, such as VDR [Rochel et al., 2000], ROR [Kallen et al., 2002]
and ROR [Stehlin et al., 2001]. However, the character and number of amino acids
linking the helices X and 12 are very critical. In case of CAR, this linker is one
methionine residue, which influences the rigidity of this region and ultimately allows
the fixation of the helix 12 in this NR. In other NRs the linker is comprised of two
residues. In case of VDR, the leucine and threonine allow higher flexibility for this
part of the LBD. This is in contrast to the occurrence of phenylalanine and proline
residues in the ROR NR subtypes. The presence of these residues helps in the fixation
of the helix 12 and thus contributes to the constitutive activity [Xu et al., 2004].
Fig. 2.5 The crystal structures of the human and mouse CAR LBDs. Both crystal
structures show a high level of similarity. Helices h2 and h2’ (orange) are highlighted in
orange. The additional helix hX (blue), located between helices h11 and h12, is depicted
in color with helix h12 in dark red.
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The short helix 12 in CAR allows for the free carboxyl group at the C-terminus to
interact with the lysine in helix 4 (K195 in human and K205 in mouse CAR) and this
interaction helps to stabilize helix 12. This lysine is conserved in many other NRs
such as VDR and PPARs. However, in the latter it interacts with an aspartate residue
located in helix 12 [Molnár et al., 2005] and helps in the stabilization of PPARs’
helix 12. In addition to this interaction, K205 (K195) together with S337 (S327) from
helix 10 also interacts with other carbonyl groups in the C-terminus of the helix 12
[Suino et al., 2004]. Furthermore, this same lysine appears to be critical for the
interaction with CoRs [Lempiäinen et al., 2005; Xu et al., 2002]. Another special
feature of CAR is the presence of the two short 310 helices 2 and 2’, which connect
helices 1 and 3 (Fig. 2.5). Although these two helices show low thermal parameters
(average b-factor = 33 Å2) they contribute to the ligand-binding pocket since an
evolutionary-conserved hydrophobic phenyalanine residue in helix 2’ (F142 in
mouse and F132 in human CAR) is part of the ligand-binding pocket. However,
residues from helices 2 and 2’ do not seem to be involved in direct interactions with
the ligands but they contribute to the hydrophobic nature of the ligand-binding
pocket. Finally, the topology suggests that this region is most likely the ligand entry
point as it was postulated for PPAR [Gampe et al., 2000; Nolte et al., 1998; Shan et al.,
2004].
The CAR ligand-binding pocket is made up from the residues from helices 2, 3, 4,
5, 6, 7 and 10 and from -sheets 3 and 4, and therefore resembles other NRs.
However, the numbers of residues that frame the pocket are different in active and
inactive mouse CAR, 31 and 27 residues, respectively [Shan et al., 2004; Suino et al.,
2004]. As it is the case for many other NRs, most of the residues in the ligand-binding
pocket of CAR have an apolar character. Two hydrophilic patches exist and they
make it possible to form hydrogen bonds with the ligands. Interestingly, the sizes of
the ligand-binding cavities of CARs are in between the classical endocrine NRs e.g
ER and RAR and the adopted orphans such as PPARs and PXR. The volumes of the
ligand-binding pockets are 525 Å3 and 570 Å3 for active and inactive mouse CAR,
respectively. For human CAR it is 675 Å3, which is more comparable to the 697 Å3 of
VDR’s ligand-binding pocket bound to its natural ligand 1,25(OH)2D3.
Although the chemical structures of the ligands bound to all four CAR LBDs are
different, they share some similarities in binding to CAR. All of them are using the
hydrophobic character of the cavities, and the hydrogen bonds formed between the
polar residues and ligands serve to orient the ligand. In mouse CAR, none of the
ligands make a direct hydrogen bond contact with the helix 12, but TCPOBOP forms
a number of hydrophobic interactions with helix 12 (L353) and the linker helix (L346,
T350). Since these interactions serve additionally for stabilization of the helix 12, they
may be responsible for the superagonistic properties of this ligand. In human CAR
neither of the ligands co-crystallized with the LBDs form direct contacts with
helix 12. The closest residue to the atoms of the ligands is L343, which is positioned
at a distance of 4.9 Å from the C21 of 5-pregnadione and 3.9 Å from the thiazole
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ring of CITCO. Between the ligand and helix 12 there is a barrier formed by residues
of F161, N165, F234 and Y326 that excludes the possibility of a direct interaction.
2.2.2 Physiological role of the CAR
The role of CAR as a xenobiotic receptor was first suggested by Honkakoski et al.
[Honkakoski et al., 1998b], who characterized the transcription factors that regulate
the expression of the CYP2B P450 cytochrome oxidase enzyme producing gene
family. Like the xenobiotic responsive enhancer module (XREM) of the CYP3A gene
promoter, the CYP2B promoter contains clusters of simple NR REs in close proximity
to each other. The phenobarbital responsive enhancer module (PBREM) of the mouse
CYP2B10 gene contains two direct repeat (DR) 4-types of response elements (REs),
which have an arrangement of two hexanucleotide half-sites with a four-nucleotide
spacer, and a nuclear factor (NF) 1-binding site at positions -2290 to -2237 relative to
the transcription start site (TSS) [Honkakoski et al., 1998b]. In human, a similar
PBREM was found at position -1733 through -1683 relative to the TSS of the CYP2B6
gene, which is the orthologue of the mouse CYP2B10 gene [Sueyoshi et al., 1999].
Mutation of one of these DR4-type REs decreased activity to one third of the wild
type activity in transfected primary hepatocytes, while simultaneous mutation of
both NR REs abolished PBREM activity [Honkakoski et al., 1998a; Paquet et al., 2000].
Recently, Wang et al. further analyzed the CYP2B6 regulatory region and were able
to identify an additional phenobarbital (PB)-responsive element located 8.5 kB
upstream of the TSS containing a DR4-type RE [Wang et al., 2003a]. Moreover, the
generation of CAR knockout mice provided definitive proof for the role of CAR in
the regulation of CYP2B expression in vivo, since these mice were unable to induce
CYP2B expression upon exposure to the mouse CAR activator PB [Wei et al., 2000].
Sugatani et al. [Sugatani et al., 2001] identified another PBREM-like cluster of
CAR REs (CAREs) in the regulatory region of the human UGT1A1 gene. The
UGT1A1 PBREM contains three CAREs and all are essential for the responsiveness of
the gene to CAR (as mediator of PB action). Surprisingly, there is only significant
binding of CAR-RXR heterodimers to one of the REs. How the three REs act together
to confer full enhancer activity was an interesting question at the start of the studies
presented here.
Phase I genes regulated by CAR in various species include members of the
CYP1A [Maglich et al., 2002], CYP3A [Maglich et al., 2002; Sueyoshi et al., 2001] and
CYP2C [Chen et al., 2003; Ferguson et al., 2002; Gerbal-Chaloin et al., 2002]
subfamilies. In addition to the phase II enzyme UGT1A1, CAR regulates, in mouse,
the expression of gluthathione S-transferases (GSTs) [Maglich et al., 2002] and
sulfotransferases (SULTs) [Maglich et al., 2003; Maglich et al., 2002]. Moreover, mouse
CAR has been shown to regulate the expression of the transporters multi-drug
resistance-associated protein (MRP) 1, MRP2 and MRP3 [Kast et al., 2002; Maglich et
al., 2002].
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2.3 PPARs
Although it was not known at the time, the first molecular sensor for fatty acids
was discovered in 1990 and was termed peroxisome proliferator-activated receptor 
(PPAR), since it was able to bind chemicals known to induce peroxisome organelle
proliferation in rodents [Issemann et al., 1990]. The organelles contribute to the
oxidation of the fatty acids.
The following years uncovered two other related receptors, PPAR and  (also
called ) [Dreyer et al., 1992; Kliewer et al., 1994].
2.3.1 3D-protein structure of the PPAR LBDs
To date (November 2005) there are 19 PPAR crystal structures available in the
Protein Data Bank (Table 2.2), and this number is expected to increase. This high
number, compared to CAR and human VDR crystal structures, reflects how
significant these receptors are for the NR research community. A simple division of
these structures can be made according to what protein molecules are in the basic
unit of the crystals (e.g. monomer or heterodimer PPAR with RXR). Another way in
which to classify these structures is according to ligand properties or whether the
structure contains CoA peptide. It is an interesting fact that, currently there is only
one structure available of a NR containing a CoR peptide. This crystal structure is
PPAR co-crystalized with the SMRT CoR peptide. For a detailed description of this
structure see Chapter 2.6.1. One of the first PPAR structures to be published was
PPAR [Nolte et al., 1998]. The authors presented the apo-PPAR LBD and a ternary
complex of PPAR-SRC1 with rosiglitazone (Fig. 2.6). These structures resembled
well the classical architecture of the canonical NR LBD of 13 -helices sandwiched in
three layers and a small four-stranded -sheet. The unique features of this LBD is the
existence of the helix 2’ between the first -sheet and helix 3. Most of the amino acids
have well-defined electron-density maps except for those which were in the loop
region between helices 2’ and 3 (Fig. 2.6), which appears to be the most thermally
mobile loop. The spatial placement of the helix 2 suggests that it is a ligand entry
point. The top part of the LBD, where helices 4, 5 and 8 are tightly packed between
the helices 1, 3, 7 and 10, shows that there is a very rigid composition of the tertiary
structure [Molnár et al., 2005; Nagy et al., 2004; Nolte et al., 1998]. This arrangement of
the helices defines well the large ligand-binding pocket.
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Table 2.2 Human PPAR crystal structures.
PDB
ID Molecules Ligand
Resolution
from PDB
header
Resolution
from map
calculation
Complete-
ness of
data
R value
(free R)
from PDB
header
R
value
for
map
Reference
1I7G PPAR Az 242 2.20 Å -* 99.3 % 0.237(0.271) -*
[Cronet et
al., 2001]
1K7L PPAR-SRC1 GW409544 2.50 Å -* 98.3 %
0.247
(0.284) -*
[Xu et al.,
2001]
1KKQ PPAR-SMRT GW6471 3.00 Å -* 98.8 %
0.258
(0.290) -*
[Xu et al.,
2002]
1GWX PPAR
2-Methyl-
propionic
acid
2.50 Å 13.18 –2.50 Å 73.1 %
0.246
(0.303) 0.269
[Xu et al.,
1999]
2GWX PPAR No ligand 2.30 Å 8.00 -2.00 Å 72.0 %
0.246
(0.288) 0.263
[Xu et al.,
1999]
3GWX PPAR
Eicosa-
pentanoic
acid
2.40 Å 19.50 -2.20 Å 60.0 %
0.242
(0.301) 0.272
[Xu et al.,
1999]
1Y0S PPAR GW2331 2.65 Å 19.76 -2.64 Å 94.5 %
0.210
(0.261) 0.226
[Takada et
al., 2000]
1PRG PPAR No ligand 2.20 Å 50.99 -2.00 Å 76.1 %
0.246
(0.318) 0.271
[Nolte et
al., 1998]
2PRG PPAR-SRC1 Rosiglitazone 2.30 Å -* 89.9 %
0.207
(0.264) -*
[Nolte et
al., 1998]
3PRG PPAR No ligand 2.90 Å 19.73 -2.91 Å 95.7 %
0.209
(0.271) 0.226
[Uppenberg
et al., 1998]
4PRG PPAR GW0072 2.90 Å -* 78.6 % 0.240(0.283) -*
[Oberfield
et al., 1999]
1I7I PPAR Az 242 2.35 Å -* 91.3 % 0.238(0.284) -*
[Cronet et
al., 2001]
1KNU PPAR
Alkyloxy-
phenylpro-
pionic Acid
2.50 Å 39.89 -2.50 Å 97.4 %
0.224
(0.264) 0.249
[Sauerberg
et al., 2002]
1NYX PPAR Ragaglitazar 2.65 Å -* 80.0 % 0.237(0.306) -*
[Ebdrup et
al., 2003]
1WM0 PPAR-TIF2
2-Benzoyl-
amino-
benzoic acid
2.90 Å 14.83 -2.81 Å 87.7 %
0.195
(0.295) 0.212
[Ostberg et
al., 2004]
1K74
PPAR-
RXR-
SRC1
GW406544
9cisRA 2.30 Å -* N/A
0.238
(0.279) -*
[Xu et al.,
2001]
1FM6
PPAR-
RXR-
SRC1
Rosiglitazone
9cisRA 2.10 Å
44.00 –
2.10 Å 87.8 %
0.250
(0.292) 0.265
[Gampe et
al., 2000]
1FM9
PPAR-
RXR-
SRC1
GI262570
9cisRA 2.10 Å
19.69 -
2.10 Å 91.9 %
0.239
0.268) 0.258
[Gampe et
al., 2000]
1RDT
PPAR-
RXR-
CoA
peptide
GI262570
2-propanoic
acid
2.40 Å -* 97.1 % 0.221(0.259) -*
[Haffner et
al., 2004]
* the electron density map is not available or cannot be calculated
Both the apo- and the holo-PPAR structures contain homodimers that probably
mimic the herodimerization with RXR, since to date there is no evidence for a
biological function of PPAR homodimers. It remains interesting that the dimerization
interface of PPAR resembles that of ER and RXR, which are both capable of
homodimerization. The protein sequence homology between PPAR and RXR is 27 %
in this region. However, several amino acids that form the strongest interaction in
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RXR homodimers are conserved in PPAR (F432, A433, L436, E418, E407 and K438 of
human PPAR1). The ligand-binding pocket of apo-PPAR is a large T-shape pocket,
which is bordered by helices 3, 6, 12 and the -sheets. The total volume of the apo-
PPAR pocket is 1300 Å3. In the holo-PPAR, rosiglitazone occupies only 40 % of the
ligand-binding pocket. This ligand makes several specific interactions with amino
acid in helices 3, 4, 10 and 12. The carbonyl group of rosiglitazone forms hydrogen
bonds with both H323 and H449. Unlike ligands for CAR, in PPAR the ligand has a
direct contact with helix 12 that helps to stabilize helix 12.
Fig. 2.6 The crystal structure of human apo- and holo-PPAR LBDs. The helices of the
LBDs are depicted in slate blue and wheat color for apo-PPAR and holo-PPAR,
respectively. The helix 12 in both LBDs is highlighted in red color. The holo-PPAR
structure contains the SRC1 peptide (white) and rosiglitazone (yellow). The most
thermally labile part of the structure is the loop between helices h2’ and h3.
The origin of this very specific contact is the second last tyrosine in the helix 12
that is conserved in all human PPARs. Except these polar interactions there are many
apolar interactions with the benzene rings and the sulphur atom of the TZD ring,
since the pocket has a hydrophobic character, as is it the case also for other NRs. The
position of the helix 12 in the apo-PPAR homodimer interestingly adopts in one
molecule an active and in the other one an inactive conformation suggesting that in
the apo-PPAR the helix 12 can assume both conformations and the ligand then acts
to lock-down the receptor into the active conformation [Nolte et al., 1998]. Although
this scenario is highly possible, detailed analysis of the crystal structure suggests that
the helix 12 of the inactive PPAR molecule contacts the helix 12 of the active
neighboring symmetry-related molecule. Thus it appears that the inactive helix 12
mimics the interaction with a CoA peptide. In the process of ligand-dependent
activation the interaction of the LBD with CoAs is required and the ternary structure
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of the crystalized complex suggests that each member of the receptor in the dimer
interacts with a single interaction motif from the CoA.
2.3.2 Physiological roles of the PPARs
All three subtypes have distinct tissue distribution and selective function in the
regulation of metabolism in the organism. In the cell they act by regulating networks
of target genes.
PPAR can be found primarily in the liver and in smaller amounts in heart and
skeletal muscle tissue, where it has a critical role in controlling fatty acid oxidation
[Reddy et al., 2001]. Under conditions of prolonged fasting or during night, fatty
acids are released from adipose tissue and transported to the liver where PPAR
becomes highly up-regulated [Kersten et al., 1999]. The activation of PPAR by fatty
acids promotes hepatic fatty acid oxidation to generate ketone bodies, providing an
energy source for peripheral tissues. This regulation is very important and is
supported by evidence derived from the PPAR-null mouse, which is unable to meet
energy requirements during fasting [Kersten et al., 1999]. The PPAR-induced fatty
acid oxidation improves plasma lipid profiles and in many mouse models PPAR
agonists have an effect on plasma triglycerides, reduce adiposity and improve
hepatic and muscle steatosis leading to improved insulin sensitivity [Chou et al.,
2002; Guerre-Millo et al., 2000; Kim et al., 2003]. This is reflected by the fact that, in
clinical practice, PPAR-selective agonists are widely used to treat
hypertriglyceridemia. However, the beneficial effect on insulin sensitivity has not
been rigorously examined.
PPAR in the beginning received less attention than the other PPARs due to its
ubiquitous expression profile in addition to lack of selective ligands. However, recent
development of specific PPAR agonists has made it possible to study more
extensively this subtype, and this receptor has turned out to be a prominent
regulator of fatty acid catabolism and energy homeostasis [Barak et al., 2002; Peters et
al., 2000]. GW501516, a PPAR selective agonist, was shown to lower plasma
triglyceride levels in obese monkeys while raising HDL levels suggesting a beneficial
effect in hyperlipidemic patients [Oliver et al., 2001]. Ectopic expression of an
activated PPAR in adipose tissue produced lean mice that are resistant to obesity
and hyperlipidemia [Wang et al., 2003b]. The mechanism of this protective effect
appears to be due to the up-regulation of genes involved in fatty acid catabolism and
adaptive thermogenesis. PPAR deficient mice fed with high-fat diet show reduced
energy uncoupling and are susceptible to obesity [Wang et al., 2003b]. All these data
suggest a role for PPAR as a fat-burning opposite to the fat-storing PPAR [Wang et
al., 2003b]. However, its potential therapeutic value in obesity and diabetes has to be
further explored.
PPAR is the most studied PPAR isoform and large amounts of evidence show
that it is a master regulator of adipocyte formation and their ability to function
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normally in the adult body [Rosen et al., 2000]. Its expression is induced during the
differentiation of fat cells, which can be mimicked via ectopic expression of this
receptor in nonadipogenic cells. These cells consequently differentiate to mature
adipocytes [Tontonoz et al., 1994]. Furthermore, PPAR null mice fail to develop
adipose tissue [Barak et al., 1999; Kubota et al., 1999; Rosen et al., 1999]. Although
adipose tissue only represents about 10 % of the insulin-stimulated glucose disposal,
it has a key role in directing whole body glucose homeostasis. The hints for this
function come from the fact that TZDs, PPAR selective agonists, act as insulin-
sensitizing drugs [Forman et al., 1995; Lehmann et al., 1995]. At the molecular level,
two plausible mechanisms have been suggested to explain this process. Firstly,
activation of PPAR in adipocytes improves their ability to store lipids, thereby
reducing lipotoxicity in muscle and liver tissue. The activation of this metabolic
pathway involves repartitioning of lipids in the body by increasing the content of
triglycerides in adipose tissue and lowering free fatty acids and triglycerides in
plasma, liver and muscle, and consequently improving insulin sensitivity [Guan et
al., 2002; Yamauchi et al., 2001]. Secondly, PPAR-agonists affect the release of
adipokines such as leptin, resistin and adiponectin, which have potent metabolic
effects on other tissues. For example, PPAR specific drugs inhibit the expression of
tumor necrosis factor  and resistin which both promote insulin resistance [Guan et
al., 2002; Peraldi et al., 1997; Rajala et al., 2003; Steppan et al., 2001]. Tissue-specific
knockout studies strengthen the conclusions that the adipose tissue is the primary
target of TZDs and suggest a critical biological role for PPAR in both muscle and
liver. These studies also provide direct evidence for a molecular link between glucose
homeostasis and lipid metabolism [Evans et al., 2004].
2.4 VDR
The first evidence for the existence of a vitamin D binding protein or receptor
was provided by Haussler and Norman in 1969 [Haussler et al., 1969]. However, for
the isolation of the full coding sequence of the human and rat receptor, one had to
wait nearly two decades until 1988 [Baker et al., 1988; Burmester et al., 1988a;
Burmester et al., 1988b]. VDR was first discovered in extracts from chicken intestine,
because this animal was used as a model system for examining the role of vitamin D
in calcium homeostasis [Pike et al., 1980]. Later on, the actions of vitamin D have
been extended beyond those identified in the intestine. The target tissues of vitamin
D include the kidney, bone, parathyroid gland as well as many others, which reflects
the fact that VDR is a widely expressed NR.
2.4.1 3D-protein structure of the VDR LBD
To date there has been six human VDR crystal structures (Table 2.3) made
available in the Protein Data Bank (PDB).
Review of Literature
Kuopio Univ. Publ. C. Nat. and Environ. Sci. 193: 1-115 (2006) 35
Table 2.3 The human VDR crystal structures.
PDB
ID
Ligand
Resolution
from PDB
header
Resolution
from map
calculation
Complete-
ness of
data
R value
(free R)
from PDB
header
R value
for
map
Reference
1DB1 1,25(OH)2D3 1.80 Å 19.94 – 1.80 Å 95.6 %
0.191
(0.214)
0.202
[Rochel et al.,
2000]
1IE8 KH1060 1.52 Å 18.53 – 1.37 Å 90.3 %
0.212
(0.230)
0.223
[Tocchini-Valentini
et al., 2001]
1IE9 MC1288 1.40 Å 14.88 – 1.40 Å 73.2 %
0.214
(0.248)
0.224
[Tocchini-Valentini
et al., 2001]
1S0Z EB1089 2.50 Å 14.95 – 2.50 Å 97.2 %
0.170
(0.204)
0.187
[Tocchini-Valentini
et al., 2004]
1S19 MC903 2.10 Å 19.90 – 2.00 Å 93.9 %
0.179
(0.214)
0.194
[Tocchini-Valentini
et al., 2004]
1TXI TX522 1.90 Å 19.83 – 1.90 Å 96.0 %
0.191
(0.218)
0.196 [Eelen et al., 2005]
The first one was solved with the natural ligand, 1,25(OH)2D3 [Rochel et al.,
2000]. The VDR molecule used for crystallization has a deletion of a hinge region
insertion domain, which acted to stabilize the LBD and allowed the formation of
crystals. The complex was solved at resolution 1.8 Å by a combination of molecular
replacement using a homology model based on the RAR [Klaholz et al., 1998;
Renaud et al., 1995] and isomorphous replacement with a mercurial derivative. The
structure has the general topology of NR LBDs with the canonical 13 -helices
sandwiched in three layers and a three-stranded -sheet (Fig. 2.7). Helices 1 and 3 are
connected via two small helices 2 and 3n.
The missing insertion domain is rather distant from the ligand-binding pocket
and therefore most likely it does not affect the ligand binding. On the other hand the
insertion domain may play a role in cofactor binding. However, this hypothesis has
not been investigated in detail. The crystal structure has the highest homology to
holo-human RAR LBD [Klaholz et al., 1998; Renaud et al., 1995]. The clearest
difference between LBDs of VDR and RAR corresponds to the connection between
helices 1 and 3, which in RAR surrounds the -sheet. Contrary to this, in VDR the
tip of the -sheet is shifted outward and thus allowing an enlargement of the ligand-
binding pocket. The position of this -sheet is very similar to that found in ER
[Brzozowski et al., 1997]. All the individual strands of -sheet have residues which
contact the ligand 1,25(OH)2D3. In the 1-sheet, W286, a very specific residue in
VDR, helps to position the ligand in the ligand-binding pocket. In addition, the
residues from the -sheets help to stabilize the connecting loop formed between
helices 2 and 3n.
Another interesting property leading to the enlargement of the ligand-binding
pocket is the shifted loop between helices 6 and 7 towards the surface of LBD. The
comparison among the various NRs showed that this loop is highly flexible. The
crucial helix 12 is in the active conformation and makes two direct van der Waals
contacts with the methyl group of the ligand via two residues V418 and F422. The
position of the helix 12 is stabilized by several hydrophobic interactions (T415, L417,
V418, L419, V421, F422) with the residues from helices 3 (D232, V234, S235, I238,
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Q239), 5 (A267, I268) and 11 (H397, Y401). In addition, the fixation of helix 12
involves two pairs of polar residues, the conserved salt bridge between K264 (helix 4)
and E420 (helix 12) and a hydrogen bond between S235 (helix 3) and T415 (helix 12).
Some of the above mentioned residues (V234, I268, H397 and Y401) directly interact
with the ligand and therefore they contribute to the ligand-induced switch of the
helix 12. The volume of the ligand-binding pocket of the receptor is 697 Å3 and
1,25(OH)2D3 occupies only 56 % of the pocket. In the space where the A-ring of the
ligand is situated, there is an enlargement of the pocket due to two water molecules
[Rochel et al., 2000]. This adaptation of the pocket can explain the activity of the 2-
methyl derivative of 1,25(OH)2D3, which shows 4-fold higher affinity than the
natural ligand [Fujishima et al., 1998].
Fig. 2.7 The crystal structure of the human VDR LBD. Helices are depicted in wheat
color with helix 12 is highlighted in red. The deleted insertion domain is between helices
h3n and h2 (orange). The ligand-binding pocket (LBP) is displayed in mesh
representation (grey). In the pocket the natural ligand 1,25(OH)2D3 is bound and is
highlighted in yellow color
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In addition, the empty space around the aliphatic chain in the pocket would
suggest that analogs with differing chain lengths could fit. Some vitamin D
derivatives [Bouillon et al., 1995] have been shown to have different effects on
transcriptional regulation and CoA recruitment [Rachez et al., 1998; Takeyama et al.,
1999]. To understand their specificity, preliminary ligand docking was made [Rochel
et al., 2000], which showed that synthetic ligands with a rigid aliphalic chain at
position C17 (MC903, EB1089), can be accommodated in the ligand-binding pocket
with only minor changes in geometry with the respect to the position of
1,25(OH)2D3. In contrast, the 20-epi analogs’ (MC1288, KH1060) C21-methyl group
points to the same part of the pocket as the natural ligand’s one while the rest of the
chain is lining the opposite side of the pocket. Ligands with longer aliphatic chain
adopt more compact conformation and form additional van der Waals contacts with
the ligand-binding pocket, which may further stabilize the LBD.
2.4.2 The physiological role of the VDR
The physiological role of vitamin D metabolites and its receptor include a variety
of processes and perhaps one of the most interesting is its biological effect on
regulation of proliferation and differentiation [Feldman et al., 1980]. These effects are
rather different from the effects of other steroid hormones. The observed
antiproliferative effects are considered to have a potential therapeutic role in the
treatment of various cancers as well as in the treatment of human psoriasis and
hyperproliferative disorders of the skin [Nagpal et al., 2001].
In mammals, the most responsive primary VDR target gene is the
24-hydroxylase (CYP24). The product of this gene is an enzyme which forms a
negative feedback loop mechanism in the vitamin D signaling due to its primary role
in inactivation of the natural ligand for VDR, 1,25(OH)2D3.
VDR is known to bind as a heterodimer with RXR to DR3-type of elements.
These elements can be found in the CYP24 promoter and this is the reason for the
strong responsiveness of this gene. The two DR3-type elements are located in the
proximal part of the promoter and are separated by a distance of less than 100 bp.
These RE clusters are evolutionary conserved between men and rodents [Kerry et al.,
1996; Zierold et al., 1995].
2.5 Cofactors
2.5.1 CoAs
CoAs represent a diverse group of proteins that have the ability to enhance
NR-mediated transcription mainly via direct interaction with the LBD of the receptor
in its active conformation. Most CoAs contain one or more NR interaction boxes,
bearing a short consensus peptide interaction motif LXXLL, where L is leucine and X
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is any amino acid [Heery et al., 1997]. This motif directly interacts with the CoA
binding groove on the surface of the LBD and its active part is the helix 12. CoA
interaction can also occur in the N-terminal part of the receptor primarily in the AF-1
domain [Wärnmark et al., 2003]. CoAs do not show such common structural themes
like NRs, they are highly diverse in both structure and function (Table 2.4). Some can
serve as adapters between NRs or other transcriptional factors and the basal
transcriptional machinery (Fig. 2.1). Many CoAs have shared characteristic
enzymatic activities that can enhance the transcriptional activity, e.g. the SRC family,
whose members have histone acetyltransferase (HAT) activity that targets histones
or other proteins at NR-regulated gene promoters for acetylation [McKenna et al.,
1999].
2.5.1.1 The SRC family of NR CoAs
This family of CoAs has been the focus of intensive study in recent years. There
are three protein members in this family each derived from a separate gene.
2.5.1.1.1 SRC-1
The first member of this family, SRC-1, was cloned using PR-LBD as a bait in
yeast-two-hybrid experiments [Oñate et al., 1995]. Although SRC-1 interacts with the
LBD of NRs in a ligand-triggered manner there have been reports that it can enhance
the activity of ER and AR through the AF-1 domain of these NRs [Alen et al., 1999;
Bevan et al., 1999; Ma et al., 1999; Webb et al., 1998]. In addition, Takeshita et al.
[Takeshita et al., 1996] and Ikeda et al. [Ikeda et al., 1999] reported the interaction of
SRC-1 with general transcription factors such as TBP and TFIIB. However, the
functional consequences of these interactions remain uncovered. Furthermore, SRC-1
can interact and enhance the activity of other transcription factors such as NF-B,
SMAD3 and AP-1, which are responsible for multiple cellular processes [Lee et al.,
1998; Na et al., 1998; Yanagisawa et al., 1999].
2.5.1.1.2 TIF-2
Human TIF2 was isolated by Voegel et al [Voegel et al., 1996] as an ER- and RAR-
interacting factor (GRIP1) and its mouse orthologue GRIP-1 by Hong et al [Hong et
al., 1996] as a GR-interacting protein. The two proteins share 94 % amino acid
identity. Both associate ligand-dependently with classical NRs such as RAR, ER and
PR in vivo. GRIP has been also shown to enhance NR receptor activity through the
AF-1 domain in addition to that of the helix 12 [Ma et al., 1999].
2.5.1.1.3 RAC3
The third member of the family was discovered simultaneously by several
groups as a RAR-interacting (RAC3), a CBP-interacting (p/CIP), a hRAR-
stimulatory protein (ACTR), a gene amplified in breast cancer (AIB-1) and a TR-
interacting protein (TRAM-1) [Anzick et al., 1997; Chen et al., 1997; Li et al., 1997;
Takeshita et al., 1996; Torchia et al., 1997]. RAC3/ACTR/AIB-1/TRAM represent the
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human protein whereas p/CIP is the mouse orthologue. In addition to the
interactions and coactivation of many NRs, p/CIP has been shown to enhance the
activity of interferon- and cAMP regulatory element binding protein (CREB),
suggesting the involvement of this CoA in multiple signaling pathways [Torchia et
al., 1997]. Furthermore, RAC3/TRAM-1 expression can be upregulated by hormone
treatment, which is another possible mechanism, how CoAs can potentiate hormone
action [Li et al., 1998; Misiti et al., 1998].
Table 2.4 The diversity of coactivators.
Coactivator
Function
Abbreviation Name
SRC-1 Steroid receptor coactivator-1
TIF2 Transcription intermediary factor 2
RAC3 Receptor-associated coactivator 3
p300 300-kD protein
Histone
acetyltransferases
CBP cAMP-response-element-binding (CREB)-binding protein
CARM1 Coactivator-associated arginine methyltransferase 1Histone
methyltransferases PRMT1 Protein arginine methyltransferase 1
Receptors or general
transcription-factor-
bridging factor
TRAP220 Thyroid-hormone-receptor-associated protein of 220 kDa
Chromatin remodeling Brg1 Brahma-related gene 1
RPF1 Receptor potentiating factor 1
E6-AP E6-associated protein
UbcH7 Ubiquitin conjugating enzyme 7
TRIP1-
mSUG1 Suppressor of Gal4-thyroid hormone interacting protein 1
MIP224 MB67-interacting protein 224
Ubiquitin proteasome
pathway
TBP-1 TATA-binding protein-1
PGC-1 PPAR coactivator-1
CoAA Coactivator activator
p72 72-kDa protein
TRBP/AIB3 Thyroid-hormone-receptor-binding-protein/amplified in breast
cancer 3
CAPER Coactivator of activating protein-1 (AP-1) and estrogen receptors
P54nrb Nuclear RNA-binding protein p54
Splicing control
p102 U5 small nuclear ribonucleoprotein particle-binding protein
SRC-1 Steroid receptor coactivator-1
TIF2 Transcription intermediary factor 2
RAC3 Receptor-associated coactivator 3
PGC-1 PPAR coactivator-1
Signal-integrating
coactivators
TORC2 Transducer of regulated CREB activity 2
Ferdinand Molnár: Structural analysis of the ligand-binding domains of CAR, VDR and PPARs
40 Kuopio Univ. Publ. C. Nat. and Environ. Sci. 179: 1-115 (2006)
2.5.1.2 Functional domains and the LXXLL motif of the SRC CoA family
The SRC family shares a common domain structure (Fig. 2.8), the most conserved
N-terminal basic loop-helix-loop (bHLH)-PAS domain, which functions in many
proteins especially in transcription factors as a DNA-binding or heterodimerization
domain. The PAS motif is also found in several transcription factors such as Period
(Per), Aryl hydrocarbon receptor (AhR) and single-minded (Sim). Although similar
to the bHLH domain, the PAS domain (Fig. 2.8) plays also an important role in
protein-protein interaction and dimerization. The function of these domains in SRC
CoAs remain unknown, though it probably mediates intra- or intermolecular
interactions. The bHLH-PAS domain is followed by a centrally located receptor
interaction domain (RID) and C-terminal transcriptional activation domain (AD).
The RID mediates ligand-dependent, direct interacions with NRs [Li et al., 1998;
Oñate et al., 1995; Voegel et al., 1996]. The detailed protein sequence analysis of this
domain identified a conserved LXXLL motif. This motif is also often called the NR
box [Heery et al., 1997].
Fig. 2.8 A representation of the functional domains found in the p160 family of CoAs.
The functional domains of the three p160 CoA family members (SRC-1, TIF-2 and RAC-3)
are visualized in cylindrical representation. The basic helix-loop-helix (bHLH) and the
PAS heterodimerization domains are located within the first 300 amino acid residues on
the N-terminus. It allows the CoAs to interact with proteins such as myogenin, MEF-2C
and TEF-4. The NR RID is placed in the middle part of the proteins. Other domains (AD1
and AD2) also contain protein interaction motifs. SRC1 contains an additional interaction
motif in the AD2 domain. The LXXLL motifs are numbered with Roman numerals (I-VII).
The activation domains (AD1 and AD2) serve for interaction also with HATs. The other
possible protein-protein interactions (P/CAF, CARM1 and p300/CBP) are shown with
black lines.
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The SRC family of CoAs has three LXXLL motifs, with additional, non-conserved
NR boxes present at different locations outside the RID (Fig. 2.8). Peptide
competition assays and site-directed mutagenesis experiments provided a solid
evidence for the requirement of LXXLL motifs in interaction with the LBDs of NRs
[Ding et al., 1998; Heery et al., 1997; Torchia et al., 1997]. In addition, protein structure
prediction and crystallographic analysis have shown that LXXLL motifs form
amphipathic -helices with the hydrophobic leucines on one side of the helix. This
-helix is then able to interact efficiently with helix 12 of the NR’s LBD. In addition,
the interacting surface of NR includes helices 3, 4 and 5, which actively participate in
creation of a LXXLL compatible hydrophobic groove where the CoA interaction
motif can fit [Darimont et al., 1998; Feng et al., 1998; Nolte et al., 1998; Shiau et al.,
1998; Torchia et al., 1997]. One of the most interesting aspects of NR box function is
that different NRs prefer different NR boxes of RID for interaction with CoAs
[Darimont et al., 1998; Ding et al., 1998; Leers et al., 1998; McInerney et al., 1998].
2.5.2 CoRs
In general, CoRs are proteins, which can mediate gene silencing through
interaction with transcription factors that bind to DNA. Several NRs, including RAR,
TR and VDR, appear to bind to their target genes in the absence of ligand and
actively repress transcription. In majority of the cases the interaction partner for
these receptors is NCoR or its homolog SMRT, which were the first identified CoRs
for NRs [Chen et al., 1995; Hörlein et al., 1995]. They are the best-characterized CoRs
and they also share high functional and structural similarities (Fig. 2.9). Since then,
several other CoRs for NRs that differ clearly from NCoR and SMRT have been
isolated. These include Alien [Dressel et al., 1999], SUN-CoR [Zamir et al., 1997],
Rip140 [Cavailles et al., 1995], Hairless [Potter et al., 2001] and SMRTER [Tsai et al.,
1999] (Table 2.5).
Table 2.5 The NR corepressors.
Corepressor
Name Abbreviation Function
NR corepressor 1 NCoR DevelopmentDifferentiation
Silencing mediator for retinoid
and thyroid hormone receptors SMRT
Development
Differentiation
Thyroid hormone receptor
interactor 15
Alien
(TRIP15)
Development
Differentiation
Small unique NR corepressor SUN-CoR DevelopmentDifferentiation
Homolog of mouse hairless Hairless Hair development
SMRT, NCoR and other CoRs harbor several domains that are critical for their
function (Fig. 2.9). There are at least three repressor domains (RDs), which mediate
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the repression function of the CoRs, since they are critical for contacting the proteins
with additional properties important for the silencing of the target genes. One of
these properties is histone deacetylation, which acts to reverse the effects of CoAs
Fig. 2.9 Functional domains in the CoRs NCoR and SMRT. The primary structure of
NCoR and SMRT is sketched from N- to C-terminus. The functional domains are
visualized in cylindrical representation. The location of the repression domains (RD1 to
RD4) and deacetylase-activating domain (DAD) are indicated within each CoR. These
domains allow the CoRs to interact with histone deacetylases (HDAC3, HDAC4/5 and
HDAC7) and they are crucial for their function. The CoRNR box/NR interaction sites
(N1, N2, and N3 in NCoR verses S1 and S2 in SMRT) that contain the
LXX(I/H)IXXX(I/L) motifs are indicated within each corepressor schematically in dark
cylinders. Transducin beta-like protein 1 (TBL1), which is part of the repression complex,
interacts with the RD1 domain. In vivo, TBL1 is bridged to HDAC3 through SMRT and
can potentiate repression by NRs such as TR. With the same domain, SIN3 is able to
interact and thus serves as a scaffold on which the corepressor complex assembles, since
it contains multiple protein-protein interaction domains.
like the SRC family members. The C-terminal domain of SMRT and NCoR contains
two or three receptor interacting domains (RIDs) crucial for their interaction with
NRs (Fig. 2.9). The primary structure of the CoR RID resembles that of the LXXLL
motif of CoAs. However, it has an extended -helical motif with the consensus
sequence LXXI/HI XXXI/L (L = leucine, I = isoleucine, H = histidine, X = any amino
acid) [Perissi et al., 1999].
NCoR and SMRT are mainly localized in the nucleus. Recent findings, however,
suggest that changes in signaling at the cell surface can activate second messenger
systems leading to posttranslational modification, such as phosphorylation of these
proteins that can induce nuclear-cytoplasmic shuttling of the CoRs. In the case of
SMRT, MAPK-directed phosphorylation has been implicated [Hong et al., 2001]. For
NCoR the phosphorylation of an associated protein, TAB2, by IKK kinase has been
reported to induce nuclear exit [Baek et al., 2002].
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2.5.2.1 The role of CoRs in transcription repression
NCoR and SMRT have distinctly different properties when they are bound to
NRs in solution, on DNA, and on target gene promoters in living cells [Hu et al.,
2001; Ishizuka et al., 2003; Makowski et al., 2003; Webb et al., 2000; Zamir et al., 1997].
They also function as CoRs for other transcription factors [Xu et al., 1998]. The
apparent evidence of non-redundant functions and the irreplaceable role of NCoR
and SMRT comes from the knockout mouse model of NCoR, which is embryonic
lethal [Jepsen et al., 2000], indicating that SMRT cannot compensate for the lack of
NCoR. The physiological importance of CoRs has been demonstrated by analyzing
the association between CoR dysfunctions and disease states in mice and humans.
For example, in the syndrome resistance to thyroid-hormone (RTH) mutated TR
fails to release CoRs in response to physiological concentrations of the hormone.
Therefore, dysfunctional gene activation through TR is causing an abnormal
physiological state [Tagami et al., 1997; Yoh et al., 1997]. NR CoRs have also been
implicated in the mechanisms of human diseases, including acute promyelocytic
leukemia due to RAR translocations [Grignani et al., 1998; Guidez et al., 1998; He et
al., 1998], acute myeloid leukemia due to the AML1-ETO translocation [Gelmetti et
al., 1998; Lutterbach et al., 1998; Wang et al., 1998], and insulin resistance due to
mutations in PPAR [Gurnell et al., 2000]. Furthermore, NCoR and/or SMRT have
been connected with cancer. In studies where chimeric NCoR-ER proteins were
created it has been shown that they lack transcriptional activity and inhibit
ER-mediated transcription in T47D and MDA-MB-231 breast cancer cells. The
chimeric proteins also repressed the growth of T47D cells when delivered to the cells
by a retroviral vector. In addition, it has been shown that decreased levels of NCoR
correlate with the acquisition of tamoxifen resistance in a mouse model system for
human breast cancer [Lavinsky et al., 1998].
2.6 The activation and inactivation of NRs from a
structural perspective
2.6.1 Active and inactive conformations of human PPAR
The superimposition of the agonist- and antagonist- bound PPAR structure
shows that the CoR binding site partially overlaps with the CoA binding site [Xu et
al., 2002] (Fig. 2.10). Compared to the CoA motif LXXLL, the CoR motif
LXXI/HIXXXI/L has one additional -helical turn. This additional turn binds to the
same region on the surface of the NR-LBD that is occupied by helix 12 in the
agonistic conformation of the LBD. Therefore, the repositioning of the helix 12 is
necessary to allow the binding of the larger CoR motif and to prevent the folding
back of the helix 12 to its active conformation.
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Fig. 2.10 Crystal structures of human PPAR LBDs co-crystalized with SRC1 and
SMRT peptides. The crystal structures of PPAR in active (1KL7) and inactive (1KKQ)
conformations are shown. The surface of the LBD is displayed in green color. The active
conformation shows the helix 12 (red) as it is fixed to the body LBD and CoA peptide
from SRC1 (orange color) can bind. Inactivation involves the repositioning of helix 12
(red color) creating a hydrophobic groove where the CoR SMRT (green color) can bind.
The two crystal structures show that the binding surfaces for CoA and CoR overlap.
In the crystal structure of PPAR LBD bound with antagonist, GW6471, adopts a
U-shaped conformation and wraps around C276 of helix 3. The amide head group
modification of GW6471 prevents the establishment of the hydrogen bond with Y464,
the conserved tyrosine contact point in helix 12 of all PPAR isoforms. Moreover, this
ligand extends to the space, which is normally occupied by Y464 and thereby
abrogates the stable position of the helix 12 in the agonist-bound conformation [Xu et
al., 2002]. However, unlike in the case of ER bound to antagonist, the helix 12 does
not occupy the CoA binding groove, but it is loosely packed against helix 3.
Although there is an overlap between the binding spaces of CoAs and CoRs there are
some differences in the binding interfaces. First, the SMRT LXXXIXXXL motif
overlays 736 Å2 of Connolly surface of PPAR whilst the SRC-1 buries only 478 Å2
suggesting the preferable binding of CoRs’ interaction motif in the presence of
antagonist over the smaller CoA motif. Second, CoR is anchored to PPAR LBD by
three hydrogen bonds between the C-terminal carbonyl and the conserved K292
from helix 3, which also interacts with the CoA. Finally, the three-turn -helical RID
of CoR deviates from the regular -helix, which helps the motif to make hydrophobic
interactions with the receptor.
The GW409544 agonist-bound human PPAR structure shares the classical
properties of the NR LBDs with its helical sandwich and a four-stranded -sheet [Xu
et al., 2001]. GW409544 adopts a U-shape conformation and its acidic head group
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forms hydrogen bonds with Y314 (helix 5) and Y464 (helix 12). This bridg e stabilizes
the C-terminus of the LBD in the active conformation allowing the formation of the
charge clamp between E462 and K292, directing the LXXLL motif of the CoA to the
hydrophobic cleft on the surface of the receptor. The amide group from the tyrosine
nitrogen of GW409544 is buried in the part of the pocket created by helices 3, 6 and
10. The rest of the ligand wraps around helix 3 and the phenyloxazol tail faces the
helices 2’, 3 and the –sheet [Xu et al., 2001].
From both structures it is obvious that the balance between CoA and CoR
binding is tightly modulated by the position of helix 12. Helix 12 senses the presence
of different ligands and recruits CoAs or CoRs that either activate or repress
transcription.
2.6.2 Active and inactive conformations of mouse CAR
Unlike the PPAR antagonist GW6471, androstanol does not contain any side
chain or other modification on its steroid backbone and thereupon it cannot extrude
helix 12 from its active conformation by creating a steric tension.
The molecular mechanism of the conformation change when androstanol is in the
pocket of LBD depends on the presence of the specific “kink” between helices 10 and
11 (Fig 2.11). Intriguingly, the conformation of the helices 10 and 11 in the
androstanol-bound mouse CAR resembles the inactive apo conformations of classical
NRs. Although this arrangement of helices 10 and 11 is present in the inactive mouse
CAR crystal structure, it is missing from the TCPOBOP agonist-bound mouse CAR
structure. The important existence of this kink is based on the hydrogen bond
between E339 and the backbone amide of Q245 that holds the kink in its position
(Fig 2.11). This interaction is considered to be important because it is conserved in
many NRs such as ER, LXR, ERR, RAR, PR, VDR, and TR. This kink has an
important role in fixing helices 10 and 11 to the loop between helices 6 and 7. This
fixation plays an important role in fortification of certain parts of ligand-binding
pocket. In the TCPOBOP-bound mouse CAR structure, E339 can potentially interact
with the ligand. However, no such interaction can be seen for androstanol [Shan et
al., 2004]. The dynamic properties of activation and inactivation of CAR are largely
different from PPAR LBD dynamics. Since the inactive mouse CAR was not
crystallized in the presence of CoR peptide, it is not possible, at this point, to make
any comparisons between the binding modes of CoA and CoR.
2.6.3 NR ligand classification
NR ligands can be classified into two main groups according to what
conformation of the LBD they are inducing and stabilizing. In the first group there
are agonists, which stabilize the receptor in an active conformation and thus promote
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Fig. 2.11 Crystal structures and schematic representations of mouse CAR LBDs in the
active and inactive conformations. Crystal structures of superagonist TCPOBOP (yellow,
left) and inverse agonist androstanol (yellow, right) bound protein structures are shown
(upper part). The hydrogen bond interaction between Q245 (helices H6-H7) E339 (helices
H10-H11) represents the “kink” that is responsible for the molecular mechanism of
inactivation via androstanol. The two additional residues Y336 and N175 displayed in the
figure are responsible for ligand recognition. The helix H12 is highlighted in red color.
The lower figures represent the two conformations in schematic views. In the active
conformation the helices H10-H11 form a compact unit (left side) that is upon the binding
of andostanol divided to two helices H10 and H11. This conformational change creates
tension, which is released via a repositioning of the helix H12. Since CoAs are unable to
bind to the LBD they dissociated allowing the CoR to bind instead of it.
the association of the LBD with CoAs. A typical example of this group is the natural
ligand of VDR, 1,25(OH)2D3, or TCPOBOP in the case of mouse CAR. In addition,
these ligands disable the interaction of the receptor with CoRs. The second group







































































